newsfilter
← Latest News
ACCESS Newswire·

9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

Positive preliminary results from Phase 2 VIBRANT study of vurolenatide in short bowel syndrome announced Vurolenatide End-of-Phase 2 meeting with FDA on track for 3Q Cash balance as of June 30, 2022 of $29.5 million; additional $20 million from previ